Pulmonologists, who are the respiratory specialists treating the rare autoimmune disorder, will be targeted in the pilot effort.
Questcor chief operating officer Steve Cartt, "We will hire a small group of new Acthar Specialists to begin calling on and educating pulmonologists about Acthar and its potential role in the treatment of this difficult-to-treat autoimmune disorder."
With expected commencement of introductory sales in the fourth quarter of 2013, the company anticipates appointing and training a small, pilot sales force of five to ten sales representatives currently.
Questcor president and chief executive officer Don Bailey said, "Our plans to increase awareness among pulmonologists treating patients suffering from respiratory manifestations of symptomatic sarcoidosis will follow the model we have used successfully for these other markets as we continue to explore the full therapeutic potential of Acthar."